Please reach out if you have additional questions.
Early stage companies spend tens of millions building expert teams and bricks and mortar spaces to obtain proof of concept. We've rolled up our sleeves in all operational aspects to help guide companies through this. Our team knows the pitfalls and offers an A-la-Cart menu of services to minimize errors. Our goal is to remain small and nimble, leveraging our knowledge and vast network in areas that will serve you best without crippling your bottom line.
Yes, eventually. The number of full time, experienced staff to run a CGT company today is staggering and in high demand. The industry has not kept pace with supply of knowledge and talent. Turnover has also been high in the last 2 years. An example where we see a need for guidance is process development. A wrong step or poor design or lack of robust science can delay or stop a program costing millions of dollars.
Since 2023 investment and growth in our industry has slowed mainly due to tighter capital markets, high cost of goods and a lack of ground breaking clinical data to name a few. Patient needs have never been higher with approximatley19 million new cases each year surfacing just in oncology with a fraction of these treated with cell and gene modified cells. The CGT industry has great promise with estimated year over year growth around 15-25% (www.alliancerm.org). With steadfast collaboration, we hope to impact this. Please contact us for more sources